Novo Nordisk
Subscribe to Novo Nordisk

The Lead

BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases

March 24, 2015 8:16 am | News | Comments

Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.

Survey: Clinical Trial Sponsors Show Improvement

March 2, 2015 11:19 am | by Andy Szal, Digital Reporter | News | Comments

Pharmaceutical companies sponsoring clinical trials showed strong improvement in their...

FDA Approves Novo Nordisk's Weight Loss Drug Saxenda

December 24, 2014 8:06 am | News | Comments

The drug, liraglutide, will be marketed under the brand name Saxenda. It is approved for obese...

Novo Nordisk Now Hiring for New Manufacturing Facility in New Hampshire

October 29, 2014 2:20 pm | News | Comments

Novo Nordisk has announced plans to hire up to 90 people at its newly-acquired manufacturing...

View Sample

FREE Email Newsletter

Jacobs Receives Pharmaceuticals Pilot Plant Contract from Novo Nordisk

October 1, 2014 8:44 am | News | Comments

Under the terms of the contract, Jacobs is providing engineering, procurement and construction management services for a new purification pilot plant project, which initially involves one purification line. The project is expected to expand Novo Nordisk’s capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs in development.

FDA Backs Novo Nordisk Injection for Obesity

September 11, 2014 5:47 pm | by The Associated Press | News | Comments

Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity. The panel of Food and Drug Administration advisers voted 14-1 that the injectable drug's benefits outweigh it risks for patients who are obese or dangerously overweight.

Novo Nordisk Buys Production Plant in New Hampshire

August 28, 2014 11:47 am | News | Comments

The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.       


Novo Nordisk Announces U.S. Launch of New Insulin Device

June 19, 2014 1:22 pm | News | Comments

Novo Nordisk announced the availability of its newest prefilled insulin delivery device Levemir® FlexTouch® (insulin detemir [rDNA origin] injection) in the United States.                          

Lilly Diabetes Drug Meets Late-Stage Goal

February 25, 2014 11:09 am | News | Comments

Lilly said that a once-weekly, 1.5-milligram dose of dulaglutide was not inferior to a daily, 1.8 milligram dose of Novo Nordisk's Victoza in a study of nearly 600 patients who were already taking metformin, an older diabetes treatment.   

Novo Nordisk Recalls Diabetes Drugs in Europe

October 28, 2013 8:37 am | News | Comments

Novo Nordisk is recalling 3 million insulin products used for diabetes treatment in 13 European countries due to a production problem that can affect the strength of the drug. The Danish drug maker says Friday's recall affects certain batches of the prefilled insulin pen NovoMix30 FlexPen.

European Regulators: No Pancreas Risk with Diabetes Meds

July 26, 2013 1:56 pm | by The Associated Press | News | Comments

The European Medicines Agency said Friday it uncovered no new evidence of pancreas-related safety issues after reviewing a group of recently approved diabetes drugs. The agency's Committee for Medicinal Products for Human Use reviewed the safety of so-called GLP-1 diabetes therapies after a study...

Target Cuts Ties with Deen; Novo Nordisk Distances

June 28, 2013 7:56 am | by ANNE D'INNOCENZIO,AP Retail Writer | News | Comments

Novo Nordisk said it and Deen have "mutually agreed to suspend our patient education activities for now." Deen, who specializes in Southern comfort food, had been promoting the company's drug Victoza since last year when she announced she had Type 2 diabetes.


Will Novo Nordisk Drop Paula Dean?

June 24, 2013 8:47 am | Videos | Comments

The Wall Street Journal discusses the Food Network’s decision to drop Paula Dean over racial slurs she made in the past. Novo Nordisk, which uses the cooking show host to promote a diabetes drug could be the next big sponsor to drop her over the controversy

Doctor’s Doubts Imperil A Lucrative Diabetes Drug

May 31, 2013 8:05 am | by By ANDREW POLLACK; New York Times News Service | News | Comments

Dr. Peter C. Butler initially declined a request by the drugmaker Merck to test whether its new diabetes drug, Januvia, could help stave off the disease in rats.  “I said, I’m not interested in your money, go away,” Butler recalled. Merck no doubt now wishes it had.

Novo Nordisk's Q1 Profit Up 28 Percent

May 1, 2013 9:30 am | by Matthew Dennis | News | Comments

Novo Nordisk announced Wednesday that first-quarter profit jumped 28 percent versus the year-ago period to 6 billion Danish kroner ($1.1 billion), boosted by higher sales of insulins and Victoza, beating analyst estimates of 5.8 billion kroner ($1 billion).

Novo Nordisk Unveils New U.S. Headquarters

April 19, 2013 1:23 pm | News | Comments

Novo Nordisk today unveiled its new U.S. headquarters. Located in Mercer County in Plainsboro, N.J., the world-class building is the result of a $225 million redevelopment project, which utilized an existing structure and sustainable materials to limit environmental impact.

Biogen Idec, Forest and Bayer Among Top Sponsors Rated by Investigative Sites in New CenterWatch Survey

March 4, 2013 7:59 am | News | Comments

More than 2,000 global investigative sites rate the best biopharmaceutical companies to work for in a new survey conducted by CenterWatch, a provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.


Novo Nordisk Shares Tumble on Drug Review Setback

February 11, 2013 8:17 am | News | Comments

Shares of Novo Nordisk are sinking in premarket trading after the Danish drugmaker said U.S. regulators want more data before they can finish their review of two long-acting insulin drugs to treat diabetes. The company said Sunday the Food and Drug Administration requested information from a study that looks at cardiovascular health before it can finish reviewing Tresiba and Ryzodeg

Danish Novo Nordisk Profit Surges

January 31, 2013 2:56 am | News | Comments

Danish pharmaceutical company Novo Nordisk A/S has reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide approved its latest range of insulin products.

Novo Nordisk Falls on FDA Insulin Review

November 7, 2012 3:08 am | News | Comments

Shares of Novo Nordisk plunged after U.S. drug regulators raised safety questions about the company's experimental long-acting insulin for patients with diabetes.  

Diabetes Drugs Boost Novo Nordisk in Q3

October 31, 2012 5:18 am | News | Comments

COPENHAGEN, Denmark (AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 35 percent in the third quarter of 2012, chiefly spurred by strong sales of its diabetes drugs.  

Analyst: Expect Diabetes Drug Market to See Strong Growth

October 12, 2012 3:58 am | News | Comments

NEW YORK (AP) — A Jefferies & Co. analyst said Thursday that sales of diabetes drugs should keep growing at a strong clip for the rest of the decade, reaching $65 billion a year in 2020.  

Diabetes Drugs Boost Novo Nordisk in Second Quarter

August 9, 2012 4:04 am | News | Comments

COPENHAGEN, Denmark (AP) — Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 29 percent in the second quarter of 2012, chiefly spurred by strong sales of its new diabetes drugs.  

FDA Approves Levemir’s Expanded Use

May 22, 2012 8:12 am | News | Comments

Novo Nordisk announced today that the FDA has approved Levemir (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes.

Novo Nordisk Inc. Appoints Robert Clark as Vice President, Regulatory Affairs

May 9, 2012 4:10 am | News | Comments

Novo Nordisk Inc., a global healthcare company with 89 years of innovation and leadership in diabetes care, announced today that Robert Clark will be joining the company's U.S. business as Vice President, Regulatory Affairs starting May 14.  

Novo Nordisk Plans 15% Expansion of U.S. Work Force in 2012

April 27, 2012 4:07 am | News | Comments

Novo Nordisk Inc. today announced plans for a nearly 15 percent expansion of its U.S. work force in 2012. Novo Nordisk has experienced solid growth over the past five years, with an approximately 10 percent increase in U.S. staff per year across a number of specialties. Recruiting is expected to start immediately.  

Novo Nordisk Issues Statement Regarding the Petition to the FDA by Public Citizen

April 20, 2012 4:29 am | News | Comments

Yesterday, Public Citizen, a US-based consumer advocacy organization filed a petition calling on the FDA to remove Novo Nordisk’s diabetes medicine Victoza® from the US market.In response, Novo Nordisk‘s US affiliate, Novo Nordisk Inc, issued the following statement

Public Citizen Wants Withdrawal of Diabetes Drug

April 19, 2012 7:15 am | by MATTHEW PERRONE,AP Health Writer | News | Comments

WASHINGTON (AP) — A consumer advocacy group is calling on government regulators to withdraw a diabetes drug from Novo Nordisk, saying the injectable medication raises the risk of thyroid cancer, pancreatitis and kidney failure.  

Supreme Court Issues Ruling in Prandin Litigation

April 18, 2012 4:24 am | News | Comments

Sun Pharmaceutical Industries Ltd. announced that the United States Supreme Court has ruled in favour of its subsidiary Caraco Pharmaceutical Laboratories, Ltd. in its' patent litigation against Novo Nordisk over Caraco's generic version of Prandin, Repaglinide Tablets.  

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.